Verici Dx Company Description

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients.

Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.

The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.

The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

Verici Dx plc

Country	United Kingdom
Founded	2020
Industry	Medical - Diagnostics & Research
Sector	Healthcare
Employees	14
CEO	Sara Barrington

Contact Details

Address: Avon House Cardiff, CF64 2EZ United Kingdom
Website	vericidx.com

Stock Details

Ticker Symbol	VRCI
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	GB00BM8HZD43
SIC Code	2835

Key Executives

Name	Position
Sara Barrington	Chief Executive Officer
David Anderson	Chief Financial Officer